◆ 會議時間:2026年9月3-5日
◆ 會議地點:比利時 布魯塞爾
◆ 會議簡介:
2026年第20屆國際肝癌協會(ILCA)年會將于2026年9月3-5日在比利時布魯塞爾舉行,會議由國際肝癌協會(ILCA)主辦,預計有來自40多個國家的800余名代表注冊參會。ILCA年會將是肝癌相關學科領域臨床、轉化和基礎研究人員、醫師以及相關專業人士的首要論壇,以分享最佳實踐和發現,推進肝癌發病機制、預防和治療方面的研究。
國際肝癌協會(ILCA)是唯一由專業從事肝癌研究的相關學科的專家組成的國際組織。ILCA通過采取橫向方法研究并匯集所有相關領域的科學家、醫生和相關專業人員,促進肝癌的發病機制、預防和治療方面的研究。ILCA目前在全球40多個國家擁有超過310名杰出的成員以及眾多的支持者,代表著流行病學、胃腸病學、肝病學、內科學、分子生物學,(介入)腫瘤學、病理學、(介入)放射學和外科/移植等眾多學科,他們共同致力于宣提高對肝癌的認識,研發出給患者帶來希望的治療方法。未經許可禁止復制摘錄轉載本站任何內容-國際醫學會議網(lingyuint.com)。
ILCA 2026 - 20th Annual Conference of the International Liver Cancer Association
Date:
3-5 September 2026
Venue:
Brussels, Belgium
The ILCA Annual Conference is the leading scientific forum in the liver cancer field connecting hundreds of international participants from all related disciplines to exchange their knowledge and best practices in general sessions, symposia, workshops and networking sessions.
下為上次會議信息:
ILCA 2025 - 19th Annual Conference of the International Liver Cancer Association
摘要征文投稿:
Abstract Submission deadline: ?Friday, 23 May 2025
Notification on the outcome of the abstract submission will be sent by email to the submitting author?mid-June 2025.
點此提交摘要>>>Submit Abstract>>>
All entries should fall under one of the below categories and can only be submitted if the results of the research were not yet available during the initial submission stage.
1. Molecular Pathogenesis, Cell Biology, and Translational Research?
2. Epidemiology, Staging, and Prognosis?
3.?Diagnosis, Imaging and Biomarkers
4.?Therapy & Miscellaneous
5.?Clinical Trials in progress?(Posters only)
注冊費:
Early-bird rates available until 29 May 2025
ILCA Member:
€ 420.00 -
3 DAYS
€ 535.00 Regular Fee
Nurses & Pharmacists - ILCA Member
€ 180.00 - 3 DAYS
€ 215.00 Regular Fee
Student - ILCA Member
€ 180.00 - 3 DAYS
€ 215.00 Regular Fee
ILCA Non- Member
€ 690.00 - 3 DAYS
€ 745.00 Regular Fee
Nurses & Pharmacists Non-Member
€ 227.00 - 3 DAYS
€ 265.00 Regular Fee
Student Non-Member
€ 227.00 - 3 DAYS
€ 265.00 Regular Fee
----
€280.00 - Virtual Pass
◆ 參會對象:醫生、醫院科室主任/副主任、住院醫師、醫院管理者、醫護人員以及從事該領域研究的科學家、研究人員、醫藥企業代表等等。
|